**Supplementary Table 4. Resistance surveillance at year 4 (week 192) and year 5 (week 240)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Week 192** | | | **Week 240** | | |
| **Category, *n*** | **TAF-TAF** | **TDF-TAF** | **All** | **TAF-TAF** | **TDF-TAF** | **All** |
| HBV DNA ≥69 IU/mL | 6 | 3 | 9 | 4 | 3 | 7 |
| Qualified for sequencing | 6 | 3 | 9 | 4 | 3 | 7 |
| Unable to sequence | 1 | 0 | 1 | 0 | 0 | 0 |
| No change from baseline | 2 | 0 | 2 | 2 | 0 | 2 |
| Polymorphic site substitution | 3 | 1 | 4 | 2 | 3 | 5 |
| Conserved site substitution | 0 | 2 | 2 | 0 | 0 | 0 |
| Qualified for phenotyping | 2 | 3 | 5 | 1 | 1 | 2 |

HBV, hepatitis B virus; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate